Showing results (2531-2540 of 10,006) with videos related to
Sort By:
Pageof 1,001
Leukemia & Lymphoma|April 21, 2011
Rituximab with pentostatin or cladribine: an effective combination treatment for hairy cell leukemia after disease recurrenceMonica Else, Claire E Dearden, Estella Matutes, et al.Leukemia & Lymphoma|May 4, 2011
Lenalidomide can induce long-term responses in patients with multiple myeloma relapsing after multiple chemotherapy lines, in particular after allogeneic transplantFrancesco Spina, Vittorio Montefusco, Claudia Crippa, et al.Leukemia & Lymphoma|May 4, 2011
Subdural hematomas in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia receiving imatinib mesylate in conjunction with systemic and intrathecal chemotherapyShiven B Patel, Ivana Gojo, Michael L Tidwell, et al.Leukemia & Lymphoma|March 23, 2011
High rate of neoplastic cells with genetic abnormalities in proliferation centers of chronic lymphocytic leukemiaZsófia Balogh, Lilla Reiniger, Hajnalka Rajnai, et al.Leukemia & Lymphoma|April 6, 2011
Trough plasma imatinib levels are correlated with optimal cytogenetic responses at 6 months after treatment with standard dose of imatinib in newly diagnosed chronic myeloid leukemiaSang Kyun Sohn, Suk Joong Oh, Byung Soo Kim, et al.Leukemia & Lymphoma|April 6, 2011
Mechanism of action of pentostatin and cladribine in hairy cell leukemiaJames B JohnstonLeukemia & Lymphoma|April 6, 2011
Purine analog toxicity in patients with hairy cell leukemiaTamar TadmorLeukemia & Lymphoma|July 16, 2019
Prognostic factors and the impact of frontline therapy in peripheral T-cell lymphoma: 10 years of 'real-world' experience from Western AustraliaJames A Kuzich, Andrew P Hutchison, Kenneth J C Lim, et al.Leukemia & Lymphoma|July 16, 2019
Clinical and pathological characteristics of Castleman disease: an observational study in a Spanish tertiary hospitalAndrés González-García, José Luis Patier de la Peña, Mónica García-Cosio, et al.Pageof 1,001